Evidence map›Paper›PMID 42459311›Full record

ArticleFrontiers in oncology2026

Homologous recombination repair and breast cancer gene testing in prostate cancer: expert perspectives and practical guidance on best practice from sample acquisition to biomarker-informed clinical decision-making.

Eva Compérat, Gunhild von Amsberg, Lynda Corrigan, Stephen P Finn, Glen Kristiansen, Angelo Minucci, David Olmos, Guilhem Roubaud

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eva CompératDepartment of Pathology, The Medical University of Vienna, Vienna, Austria.
Gunhild von AmsbergUniversity Cancer Center Hamburg and Martini-Klinik, University Hospital Hamburg Eppendorf, Hamburg, Germany.
Lynda CorriganDepartment of Medical Oncology, Tallaght University Hospital, Dublin, Ireland.
Stephen P FinnCancer Molecular Diagnostics, Trinity St. James's Cancer Institute, Dublin, Ireland.
Glen KristiansenInstitute of Pathology, University Hospital Bonn, Bonn, Germany.
Angelo MinucciDepartmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
David OlmosInstituto de Investigación Hospital 12 de Octubre, Hospital Universitario 12 de Octubre, Madrid, Spain.
Guilhem RoubaudDepartment of Medical Oncology Institut Bergonié Bordeaux, Bordeaux, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prostate cancer (PCa) treatment landscape, particularly metastatic PCa, is rapidly evolving, with an increase in personalised treatment approaches and therapy selection being guided by tumour genomics. However, PCa remains the third leading cause of death among male-specific cancers in the European Union. Nearly a quarter of patients with metastatic PCa harbour homologous recombination repair (HRR) pathway mutations, with approximately 12% harbouring alterations in the

Indexed as

BRCA mutationsclinical decision-makinggermline and somaticHRRliquid biopsymolecular diagnosticsPARP inhibitorsprostate cancer

Identifiers

PMID42459311
PMCPMC13368679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.